GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (MEX:VRTX) » Definitions » Shiller PE Ratio

Vertex Pharmaceuticals (MEX:VRTX) Shiller PE Ratio : 73.27 (As of May. 04, 2025)


View and export this data going back to 2013. Start your Free Trial

What is Vertex Pharmaceuticals Shiller PE Ratio?

As of today (2025-05-04), Vertex Pharmaceuticals's current share price is MXN9360.00. Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 was MXN127.74. Vertex Pharmaceuticals's Shiller PE Ratio for today is 73.27.

The historical rank and industry rank for Vertex Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

MEX:VRTX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 60.47   Med: 87.28   Max: 8209.67
Current: 80.52

During the past years, Vertex Pharmaceuticals's highest Shiller PE Ratio was 8209.67. The lowest was 60.47. And the median was 87.28.

MEX:VRTX's Shiller PE Ratio is ranked worse than
78.91% of 147 companies
in the Biotechnology industry
Industry Median: 32.25 vs MEX:VRTX: 80.52

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was MXN72.995. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is MXN127.74 for the trailing ten years ended in Dec. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vertex Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Vertex Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Shiller PE Ratio Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 155.85 86.51 71.14 69.46 64.70

Vertex Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 69.46 64.13 89.21 80.62 64.70

Competitive Comparison of Vertex Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Vertex Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Shiller PE Ratio falls into.


;
;

Vertex Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Vertex Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=9360.00/127.74
=73.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Vertex Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=72.995/133.1571*133.1571
=72.995

Current CPI (Dec. 2024) = 133.1571.

Vertex Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -12.653 99.621 -16.912
201506 -12.238 100.684 -16.185
201509 -6.590 100.392 -8.741
201512 -5.330 99.792 -7.112
201603 -2.926 100.470 -3.878
201606 -4.808 101.688 -6.296
201609 -3.094 101.861 -4.045
201612 2.680 101.863 3.503
201703 18.641 102.862 24.131
201706 1.265 103.349 1.630
201709 -7.441 104.136 -9.515
201712 7.659 104.011 9.805
201803 14.716 105.290 18.611
201806 15.720 106.317 19.689
201809 9.352 106.507 11.692
201812 117.221 105.998 147.256
201903 19.980 107.251 24.806
201906 19.785 108.070 24.378
201909 4.343 108.329 5.338
201912 42.058 108.420 51.654
202003 53.696 108.902 65.656
202006 73.401 108.767 89.860
202009 55.890 109.815 67.770
202012 45.752 109.897 55.436
202103 50.898 111.754 60.646
202106 5.176 114.631 6.012
202109 67.443 115.734 77.596
202112 61.542 117.630 69.666
202203 58.937 121.301 64.698
202206 62.969 125.017 67.069
202209 72.213 125.227 76.786
202212 61.412 125.222 65.304
202303 48.487 127.348 50.699
202306 60.347 128.729 62.423
202309 69.153 129.860 70.909
202312 62.974 129.419 64.793
202403 69.870 131.776 70.602
202406 -255.016 132.554 -256.177
202409 78.958 133.029 79.034
202412 72.995 133.157 72.995

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vertex Pharmaceuticals  (MEX:VRTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Vertex Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.